Table of Contents Table of Contents
Previous Page  407 / 812 Next Page
Information
Show Menu
Previous Page 407 / 812 Next Page
Page Background

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805

S403

Objective

To evaluate the prevalence of residual symptoms (both

depressive and manic) in euthymic patients with bipolar disorder

and seek for associated factors.

Methodology

A total of 30 patients with bipolar disorder were

enrolled for this study. They were in remission for at least two

months. The patients answered the Hamilton Depression Rating

Scale and the Disorder Questionnaire Mood Hirschfeld (the MDQ

scale).

Results

The average age of our patients was 43

±

13 years.

Most patients were from a rural area (70%), married (60%) and did

not go beyond secondary school level (93.3%).

Forty percent (40%) had organic personal history.

Social dysfunction was found in 40% of cases, and professional dif-

ficulties in 30% of patients.

Depressive residual symptoms were found in 33.3% in cases and

hypomaniac ones in 26.6%.

Residual depressive symptoms were significantly more frequent

among married patients and having organic personal history

(

P

= 0.025).

The professional difficulties were associated with male gender

(

P

= 0.025) and the poor quality of free interval (

P

= 0.03).

Conclusion

These results illustrate that the “intercritical phase”

in bipolar disorder is not really euthymic. These findings are

in favour of developing interventions to manage subthreshold

symptoms to reduce their impact on social and professional

functioning.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1151

EV167

Evolution of inflammatory

dysregulation and oxidative stress in

patients with first episode of mania

S. García

1 , 2 ,

, P . L

ópez Pe˜na

1 , 2 , I. Z

orrilla

1 , A.

García-Alocen

1 ,

M. Martínez-Cengotitabengoa

1 , 3 , 4 , C . B

ermúdez-Ampudia

1 ,

K.S. Mac-Dowell

5 , 6 , S . R

odríguez

5 , J.C

. Leza

5 , 6 ,

A. González-Pinto

1 , 2 , 4

1

University Hospital of Araba Santiago, Psychiatry, Vitoria-Gasteiz,

Spain

2

University of the Basque Country, neuroscience, Bizkaia, Spain

3

National Distance Education University UNED, Associated Center of

Vitora, Vitoria, Spain

4

Biomedical Research Centre in Mental Health Network CIBERSAM,

Psychiatry, University Hospital of Araba, Vitoria, Spain

5

Faculty of Medicine, Complutense University and Health Research

Institute-IIS-12 de Octubre Hospital i + 12, Pharmacology, Madrid,

Spain

6

Biomedical Research Centre in Mental Health Network CIBERSAM,

Pharmacology, Faculty of Medicine, Complutense University, Madrid,

Spain

Corresponding author.

Introduction

Recent studies have focused on the imbalance in

inflammatory and antioxidant pathways as possible causes of the

underlying neurodegenerative processes in bipolar disorder. Thus,

the study of these pathways in first episodes of mania (FEM) can

increase knowledge about this issue.

Aim

To compare plasma concentrations of pro-inflammatory

(MCP-1, PGE2, TNF ) and oxidative parameters (TAS, NO

2

and

TBARS) between controls and FEM patients and to analyze the evo-

lution of these parameters in patients from baseline to 6 months

assessment time.

Methods

This study included 44 FEMpatients and 79healthy con-

trols, aged 18 to 40. Blood samples were available for controls at

baseline and for patients at baseline and 6 months after. TAS and

TBARS were measured using non-EIA assay kits, N0

2

was measured

with Griess method and PGE2, MCP-1 and TNF with ELISA kits.

Results

At baseline, TAS was significantly lower in patients than

in controls and TBARS, MCP-1 and TNF were significantly higher

in patients. Among patients, TAS andMCP1 were lower at 6 months

than at the illness onset and PGE2 andNO

2

were significantly higher

than at baseline.

Conclusion

Patients presented an increased oxidative damage

and also a higher activation of pro-inflammatory pathways than

healthy controls at baseline. After 6 months their level of oxidative

stress continue increased. Pro-inflammatory parameters decreased

overtime (MCP-1 and TNF ) but PGE2, increased surprisingly. This

can be due to the fact that antipsychotics are not able to completely

reverse baseline inflammation.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1152

EV168

Treatment of bipolar patients in

manic phase: A comparison between

asenapine and aripiprazole

L. Girardi

, S. Gili , E. Gambaro , E. Di Tullio , E. Gattoni ,

E. Grossini , S. Farruggio , L. Mora , C. Gramaglia , P. Zeppegno

Università del Piemonte Orientale, Translational Medicine, Novara,

Italy

Corresponding author.

Introduction

Agitation is the most evident symptom in an acute

manic episode. It can be defined as excessive motor or verbal

activity that can degenerate into aggressive behaviour. Both arip-

iprazole and asenapine are indicated for the treatment of agitation

in patients with manic episode.

Aims

To retrospectively evaluate the acute effects of drug ther-

apy on psychomotor agitation rated with the PANSS-EC, the change

in manic symptoms through the YMRS, the QoL with the SF-36v2

and the cardiometabolic effects of the new oral APS.

Methods

We administered the following tests to 13 patients with

DBI at T0 (baseline), T1 (after 1 week), T2 (after 4 weeks), T3 (after

12 weeks) and T4 (after 24 weeks): PANSS-EC, YMRS, SF-36v2, CGI-

BD, CGI-S, HAM-D, BPRS. We also considered weight, height, BMI,

ECG and complete blood count.

Results

Patients recruitment and statistical analyses are still in

progress. Our preliminary results suggest that there is not amarked

difference between the two drugs. We highlighted that there has

been a noticeable decrease in results at PANSS as well as at YMRS

from T0 to T4 and patients showed an improvement in QoL. Only

one patient treated with asenapine showed an increase in the

results of HAM-D.

Conclusions

Results suggest the efficacy of the two new APS but

further recruitment and data collection are needed to better under-

stand their impact on agitation and QoL, including the metabolic

profile, with the aim to help clinicians to make a more accurate

choice of drug for each specific patient.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1153

EV169

Depot aripiprazole as maintenance

treatment in bipolar disorder: Report

of a case

C. Gómez Sánchez-Lafuente

1 ,

,

R. Reina Gonzalez (General Practitioner)

2

, A. De Severac Cano

1

,

I. Tilves Santiago

1

, F. Moreno De Lara

1

, E. Mateos Carrasco

1

1

Hospital Universitario Virgen de la Victoria, Psychiatry, Málaga,

Spain

2

Hospital General Regional Universitario, Málaga, Spain

Corresponding author.